These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1023 related items for PubMed ID: 32204691
21. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Levi C, Frémeaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-Soussan R. Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176 [Abstract] [Full Text] [Related]
22. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding. Fujita Y, Terashita M, Yazawa M, Yamasaki Y, Imamura T, Kibayashi J, Sawai T, Hidaka Y, Ohtani K, Inoue N, Shibagaki Y. Intern Med; 2020 Dec; 59(1):93-99. PubMed ID: 31902910 [Abstract] [Full Text] [Related]
23. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury. Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F. Am J Nephrol; 2018 Dec; 48(3):225-233. PubMed ID: 30205388 [Abstract] [Full Text] [Related]
24. Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation. Stea ED, Skerka C, Accetturo M, Pesce F, Wiech T, Hartman A, Pontrelli P, Conserva F, Castellano G, Zipfel PF, Gesualdo L. Front Immunol; 2022 Dec; 13():1008294. PubMed ID: 36451836 [Abstract] [Full Text] [Related]
25. De novo thrombotic microangiopathy after kidney transplantation. Garg N, Rennke HG, Pavlakis M, Zandi-Nejad K. Transplant Rev (Orlando); 2018 Jan; 32(1):58-68. PubMed ID: 29157988 [Abstract] [Full Text] [Related]
32. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S. Exp Hematol Oncol; 2017 Jan; 6():4. PubMed ID: 28101432 [Abstract] [Full Text] [Related]
33. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170 [Abstract] [Full Text] [Related]
34. The use of eculizumab in gemcitabine induced thrombotic microangiopathy. Krishnappa V, Gupta M, Shah H, Das A, Tanphaichitr N, Novak R, Raina R. BMC Nephrol; 2018 Jan 12; 19(1):9. PubMed ID: 29329518 [Abstract] [Full Text] [Related]
35. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. J Nephrol; 2021 Oct 12; 34(5):1581-1590. PubMed ID: 33826112 [Abstract] [Full Text] [Related]
36. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. J Thromb Haemost; 2014 Sep 12; 12(9):1440-8. PubMed ID: 24853860 [Abstract] [Full Text] [Related]